1 |
Yoon HJ, Choi HY, Kim YK, Song YJ, Ki M. Prevalence of fungal infections using National Health Insurance data, 2009-2013, Republic of Korea. Epidemiol Health 2014;36:e2014017.
|
2 |
Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical lndications. Infect Dis Clin North Am 2016;30(1):51-83.
DOI
|
3 |
Lee R, Cho SY, Lee DG. Fundamentals of mycology for infection control and prevention. Korean J healthc assoc Infect Control Prev 2020;25(2):86-99.
DOI
|
4 |
Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract 2012;12(1):45-56.
DOI
|
5 |
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multinational prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017;3(4):57-85.
DOI
|
6 |
Summers KH, Puenpatom RA, Rajan N, Ben-Joseph R, Ohsfeldt R. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ 2011;14(4):390-6.
DOI
|
7 |
Healthcare Bigdata Hub. Current status of hospitals and pharmacies nationwide. Available from https://opendata.hira.or.kr/op/opc/selectOpenData.mo?sno=11925. Accessed May 5, 2022.
|
8 |
Ministry of Food and Drug Safety. Information on pharmaceuticals. Available from https://nedrug.mfds.go.kr/searchDrug. Accessed May 5, 2022.
|
9 |
Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. J Dermatolog Treat 2021;32(7):783-7.
DOI
|
10 |
HIRA. Drug Utilization Review (DUR). Available from https://www.hira.or.kr/eng/about/05/01/04/index.html. Accessed May 5, 2022.
|
11 |
de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the national pharmacovigilance centre in the netherlands: an explorative observational study. Br J Clin Pharmacol 2019;85(7):1507-15.
DOI
|
12 |
Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drugdisease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996;14(5):447-50.
DOI
|
13 |
Poluzzi E, Raschi E, Motola D, Moretti U, Ponti FD. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010;33(4):303-14.
DOI
|
14 |
Salem M, Reichlin T, Fasel D, Leuppi-Taegtmeyer A. Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports. Glob Cardiol Sci Pract 2017;2017(2):11.
|
15 |
Lo Re V 3rd, Carbonari DM, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 2016;129(3):283-91.
DOI
|
16 |
Nilsson L, Borgstedt-Risberg M, Brunner C, et al. Adverse events in psychiatry: a national cohort study in Sweden with a unique psychiatric trigger tool. BMC Psychiatry 2020;20(1):44.
DOI
|
17 |
Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol 2008;64(10):999-1004.
DOI
|
18 |
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott) 2016;149(3):139-52.
DOI
|
19 |
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17(1):230.
DOI
|
20 |
Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001;52(2):201-4.
DOI
|
21 |
Kainz K, Bauer MA, Madeo F, Carmona-Gutierrez D. Fungal infections in humans: the silent crisis. Microb Cell 2020;7(6):143-5.
DOI
|
22 |
Healthcare Bigdata Hub. Drug status. Available from http://opendata.hira.or.kr. Accessed March 10, 2022.
|
23 |
Park CJ, Park YA, Ok SS, Gye MC. Effects of azole fungicide on amphibian: Review. Korean J Environ Biol 2014;32(1):1-15.
DOI
|
24 |
The Korea Institute of Drug Safety and Risk Management. Pharmacovigillance. Available from https://www.drugsafe.or.kr/iwt/ds/en/report/WhatIsKAERS.do. Accessed May 5, 2022.
|
25 |
Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993;26(2):133-46.
DOI
|